Printer Friendly

COPLEY PHARMACEUTICAL, INC. ANNOUNCES AGREEMENT FOR DEVELOPMENT, MANUFACTURING AND MARKETING OF OCULAR PRODUCTS

 CANTON, Mass., March 22 /PRNewswire/ -- Copley Pharmaceutical, Inc. (NASDAQ: CPLY) today announced its agreement with Ocular Research of Boston, Inc. (ORB) to manufacture and market a series of new ophthalmic solutions developed and patented by ORB. The new solutions include lubricating and rewetting solutions for contact lenses sold by prescription, as well as over-the-counter artificial tear preparations. Clinical trials for the ORB solutions have been completed and a PMA has been filed with the FDA based on a study of over 200 subjects.
 The ORB eye solutions adopt a new approach, using specialized lipids, including phospholipids, to reconstruct and thicken the tear film which improves lubricating and prevents drying of the eyes without blurring vision. The ORB eye solutions can be used with or without contact lenses.
 Jane C.I. Hirsh, president and CEO of Copley Pharmaceutical, said, "The new products, when FDA approved, will permit Copley to enter into a new market."
 "Eye problems are affecting an increasing number of people because of our aging population, prolonged use of computers in the workplace and at home, widespread use of contact lenses, and ocular side effects of several diseases," said Dr. Donald R. Korb, a Boston optometrist and founder of ORB.
 Copley Pharmaceutical, Inc. develops, manufactures and markets a broad range of generic, prescription and over-the-counter pharmaceutical products in a wide variety of dosage forms.
 -0- 3/22/93
 /CONTACT: Dr. Mark Hirsh, executive vice president, marketing and business development, 800-325-6111 or 617-821-6111/
 (CPLY)


CO: Copley Pharmaceutical, Inc., Ocular Research of Boston, Inc. ST: Massachusetts IN: MTC SU: LIC

DJ-TM -- NE009 -- 8128 03/22/93 10:15 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 1993
Words:268
Previous Article:ADVANCED MAMOGRAPHY SYSTEMS, INC. ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION BY UNDERWRITER
Next Article:IMRE: MORE TTP/HUS DATA TO BE REQUIRED
Topics:


Related Articles
PERRIGO TO MARKET MICONAZOLE CREAM VIA A JOINT PRODUCT AGREEMENT WITH COPLEY PHARMACEUTICAL, INC.
COPLEY PHARMACEUTICAL ANNOUNCES FDA APPROVAL FOR MICONAZOLE NITRATE VAGINAL CREAM
COPLEY PHARMACEUTICAL, INC. REPORTS YEAR-END RESULTS, SETS 3:2 STOCK SPLIT AND ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF LIDOCAINE HYDROCHLORIDE JELLY 2 PERCENT
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF FLUPHENAZINE HYDROCHLORIDE ELIXIR USP
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF HEPTALAC (LACTULOSE SOLUTION USP), 10G/15ML AND EVALOSE (LACTULOSE SOLUTION USP), 10G/15ML
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF METHAZOLAMIDE TABLETS USP, 25 & 50 MG
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF ETHOSUXIMIDE SYRUP, 250MG/5ML
HOECHST CELANESE, COPLEY PHARMACEUTICAL ANNOUNCE AGREEMENT FOR HOECHST CELANESE TO ACQUIRE 51 PERCENT OF COPLEY FOR $55 PER SHARE IN CASH
GOVERNOR WELD TO OFFICIALLY DEDICATE THE OPENING OF COPLEY PHARMACEUTICAL'S NEW FACILITY IN CANTON, MA

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters